KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Revenue (2016 - 2025)

Neogenomics (NEO) has disclosed Revenue for 16 consecutive years, with $190.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 10.56% year-over-year to $190.2 million, compared with a TTM value of $727.3 million through Dec 2025, up 10.11%, and an annual FY2025 reading of $727.3 million, up 10.11% over the prior year.
  • Revenue was $190.2 million for Q4 2025 at Neogenomics, up from $187.8 million in the prior quarter.
  • Across five years, Revenue topped out at $190.2 million in Q4 2025 and bottomed at $115.5 million in Q1 2021.
  • Average Revenue over 5 years is $148.7 million, with a median of $149.4 million recorded in 2023.
  • Peak annual rise in Revenue hit 39.95% in 2021, while the deepest fall reached 3.27% in 2021.
  • Year by year, Revenue stood at $125.7 million in 2021, then grew by 10.32% to $138.7 million in 2022, then increased by 12.15% to $155.6 million in 2023, then rose by 10.57% to $172.0 million in 2024, then rose by 10.56% to $190.2 million in 2025.
  • Business Quant data shows Revenue for NEO at $190.2 million in Q4 2025, $187.8 million in Q3 2025, and $181.3 million in Q2 2025.